<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655771</url>
  </required_header>
  <id_info>
    <org_study_id>0083</org_study_id>
    <nct_id>NCT01655771</nct_id>
  </id_info>
  <brief_title>TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated&#xD;
      by the body and to evaluate whether it is safe and well tolerated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>Based on samples collected 0-96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Based on samples collected 0-96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>Days 1-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number patients with abnormal vital sign measurements</measure>
    <time_frame>Days 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal clinical laboratory results</measure>
    <time_frame>Days 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal corrected QTc interval</measure>
    <time_frame>Days 1-5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1211 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Younger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1211 Dose 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211 Dose 1</intervention_name>
    <arm_group_label>Elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211 Dose 2</intervention_name>
    <arm_group_label>Younger</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For the elderly cohort, nonsmoking 65 to 85 years, inclusive. For the young cohort,&#xD;
             nonsmoking 18 to 45 years, inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) should be 18 to 36 kg/m2, inclusive.&#xD;
&#xD;
          -  At screening, sitting or supine heart rate of 50 to 100 beats per minute and sitting&#xD;
             or supine systolic and diastolic blood pressure of 90 to 150 mm Hg and 50 to 90 mm Hg,&#xD;
             respectively (2 of 3 measurements)&#xD;
&#xD;
          -  Subjects with mild, chronic, stable disease (e.g., controlled hypertension,&#xD;
             non-insulin-dependent diabetes, arthritis) may be enrolled if deemed medically&#xD;
             acceptable by the investigator&#xD;
&#xD;
          -  Negative for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus&#xD;
             antibody within the last 3 months&#xD;
&#xD;
          -  No clinically relevant abnormalities in laboratory evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant respiratory, gastrointestinal, renal,&#xD;
             hepatic, endocrine, hematological, neurological (including chronic headache, current&#xD;
             or prior psychiatric disease/condition, stroke), cardiovascular, psychiatric,&#xD;
             musculoskeletal, genitourinary, immunological, or dermatological disorders. Subjects&#xD;
             with mild, chronic, stable disease (e.g., controlled hypertension, controlled&#xD;
             hypercholesterolemia, non insulin-dependent diabetes, osteoarthritis) may be enrolled&#xD;
             if condition is well controlled and not anticipated to interfere with the objectives&#xD;
             of the study.&#xD;
&#xD;
          -  Any clinically significant abnormal ECG (electrocardiogram).&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational drug or medical device&#xD;
             within 60 days.&#xD;
&#xD;
          -  Donation of â‰¥500 mL blood, or equivalent, within 8 weeks prior to admission day.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, would confound or&#xD;
             interfere with evaluation of safety, tolerability, or PK of the investigational drug&#xD;
             or prevent compliance with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid induced constipation</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

